title: Potential coverage of circulating HPV types by current and developing vaccines in a group of women in Bosnia and Herzegovina with abnormal Pap smears.
abstract: The objectives of this study were to identify human papillomavirus (HPV) genotypes in a group of Bosnian-Herzegovinian women with abnormal cytology and to assess their potential coverage by vaccines. HPVs were identified by multiplex real-time PCR test (HPV High Risk Typing Real-TM; Sacace Biotechnologies, Italy) of 105 women with an abnormal cervical Pap smear and positive high-risk (HR) HPV DNA screening test. The most common genotypes in the study were HPV-16 (32·6%, 48/147), HPV-31 (14·3%, 21/147), HPV-51 (9·5%, 14/147) and HPV-18 (7·5%, 11/147). The overall frequency of HR HPV-16 and/or HPV-18, covered by currently available vaccines [Gardasil® (Merck & Co., USA) and Cervarix®; (GlaxoSmithKline, UK)] was lower than the overall frequency of other HPVs detected in the study (40·1%, 59/174, P = 0·017). Group prevalence of HR HPVs targeted by a nine-valent vaccine in development (code-named V503) was higher than total frequency of other HPVs detected (68·0%, 100/147, P < 0·001). Development of cervical cytological abnormalities was independent of the presence of multiple infections (χ 2 = 0·598, P = 0·741). Compared to other HPVs, dependence of cervical diagnosis and HPV-16, -18 (P = 0·008) and HPV-16, -18, -31 (P = 0·008) infections were observed. Vaccines targeting HR HPV-16, -18 and -31 might be an important tool in the prevention of cervical disease in Bosnia and Herzegovina.
authors.affiliation: University Clinical Centre - Sarajevo,Department of Clinical Microbiology,Bolnička 25,Sarajevo,Bosnia and Herzegovina.
authors.forename: I
authors.identifier: http://orcid.org/0000-0003-3793-2154
authors.initials: I
authors.lastname: Salimović-Bešić
authors.affiliation: International Burch University,Department of Genetics and Bioengineering,Francuske revolucije bb,Ilidža,Sarajevo,Bosnia and Herzegovina.
authors.forename: M
authors.initials: M
authors.lastname: Hukić
mesh_terms: D000328:Adult; D065309:Atypical Squamous Cells of the Cervix; D017522:Bosnia and Herzegovina; D060085:Coinfection / Q000821:virology; D004279:DNA, Viral / Q000032:analysis; D055808:Drug Discovery; D005260:Female; D005838:Genotype; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D052162:Human papillomavirus 16 / Q000235:genetics / Q000302:isolation & purification; D052161:Human papillomavirus 18 / Q000235:genetics / Q000302:isolation & purification; D058952:Human papillomavirus 31 / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D008875:Middle Aged; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000235:genetics / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000821:virology*; D053918:Papillomavirus Vaccines; D002583:Uterine Cervical Neoplasms / Q000821:virology*; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000821:virology*
chemical_list: D004279:DNA, Viral; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18
keywords: Cervical cancer; HPV type; HPV vaccines; V503; high-risk HPV; hybrid capture 2